Sharemaestro company-news research for Regencell Bioscience Holdings Ltd (RGC), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

RGC news sentiment

Regencell Bioscience Holdings Ltd

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score45Neutral is 50
Early balanced news score 31/100 evidence confidence 94% direct company focus 20 current stories across 7 publishers
Latest weekly closeUSD 5.41week of 7 Aug 2026
Main news subjectEarnings80/100 share of current news
News data statusPartial6 duplicate stories removed

Current company news

Early balanced news score

20 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone38/100 Published 30-day score45/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Regencell Bioscience Holdings L (RGC) Stock Analysis: Navigating the Volatility in Hong Kong’s TCM Innovator DirectorsTalk Interviews · 10 Aug 2026 09:21 · Source lookup

What supports the score

Direct evidence

20 current stories are mapped specifically to RGC.

Source breadth

The score uses 7 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.596.

Confidence

Confidence is 31/100, below the threshold for a firm score.

45/100
News scoreEarly balanced news score
31/100
Confidencethin evidence
94%/100
Company news20 company stories
78/100
Story agreement22/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
16 Jul: 1 stories21 Jul: 1 stories22 Jul: 1 stories25 Jul: 1 stories26 Jul: 1 stories27 Jul: 4 stories28 Jul: 2 stories01 Aug: 1 stories02 Aug: 2 stories04 Aug: 1 stories06 Aug: 1 stories09 Aug: 1 stories10 Aug: 1 stories 16 Jul: tone 21, 1 stories21 Jul: tone 50, 1 stories22 Jul: tone 23, 1 stories25 Jul: tone 50, 1 stories26 Jul: tone 50, 1 stories27 Jul: tone 50, 4 stories28 Jul: tone 50, 2 stories01 Aug: tone 73, 1 stories02 Aug: tone 50, 2 stories04 Aug: tone 21, 1 stories06 Aug: tone 73, 1 stories09 Aug: tone 21, 1 stories10 Aug: tone 50, 1 stories 95505
16 Jul31 Jul14 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence12
0.596 after freshness weighting
Source breadth100
7 independent publishers
Company relevance94
share tied directly to this company
Freshness28
recency-weighted evidence
Agreement78
how closely stories agree
Publisher mix56
less reliance on one publisher

Price and news history

News score and weekly price over 26 weeks

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb 2026: close 31.22, indexed 100.020 Feb 2026: close 29.17, indexed 93.427 Feb 2026: close 26.23, indexed 84.006 Mar 2026: close 23.35, indexed 74.813 Mar 2026: close 23.23, indexed 74.420 Mar 2026: close 27.37, indexed 87.727 Mar 2026: close 25.67, indexed 82.203 Apr 2026: close 30.8, indexed 98.710 Apr 2026: close 28.82, indexed 92.317 Apr 2026: close 28.67, indexed 91.824 Apr 2026: close 27.49, indexed 88.101 May 2026: close 29.12, indexed 93.308 May 2026: close 29.28, indexed 93.815 May 2026: close 28.58, indexed 91.522 May 2026: close 25.8, indexed 82.629 May 2026: close 23.9, indexed 76.605 Jun 2026: close 19.99, indexed 64.012 Jun 2026: close 18.83, indexed 60.319 Jun 2026: close 12.01, indexed 38.526 Jun 2026: close 6.48, indexed 20.803 Jul 2026: close 6.37, indexed 20.410 Jul 2026: close 5.88, indexed 18.817 Jul 2026: close 5.02, indexed 16.124 Jul 2026: close 5.72, indexed 18.331 Jul 2026: close 6.18, indexed 19.807 Aug 2026: close 5.41, indexed 17.3 26 Jun 2026: news score 47, close 6.48, 5 stories4703 Jul 2026: news score 49, close 6.37, 9 stories4910 Jul 2026: news score 47, close 5.88, 10 stories4717 Jul 2026: news score 42, close 5.02, 14 stories4224 Jul 2026: news score 45, close 5.72, 13 stories4531 Jul 2026: news score 48, close 6.18, 17 stories4807 Aug 2026: news score 50, close 5.41, 20 stories50
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price-82.7%latest close 5.41
News score change+3first to latest comparable week
One-week response-12.5%Price reacting lower
Fair-value position-34.0%Below fair value
WeekNews scoreCloseWeekly move
07 Aug 202650USD 5.41-12.5%
31 Jul 202648USD 6.18+8.0%
24 Jul 202645USD 5.72+13.9%
17 Jul 202642USD 5.02-14.6%
10 Jul 202647USD 5.88-7.7%
03 Jul 202649USD 6.37-1.7%
26 Jun 202647USD 6.48-46.0%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings6211 stories · 55%
Market update505 stories · 25%
Regulatory and legal213 stories · 15%
Balance sheet501 stories · 5%

Source mix

Where the evidence comes from

56/100 independence
TradingKey6511 stories · 55%
The National Law Review213 stories · 15%
MarketBeat292 stories · 10%
Investing.com Canada211 stories · 5%
DirectorsTalk Interviews501 stories · 5%
TradingView501 stories · 5%
ChartMill501 stories · 5%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences14Finance11Financial Markets10Earnings10

Earlier readings

How the score has changed

26 comparable readings · 54 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move-450 to 46 · Weakening
Observed range41–5150 is the neutral baseline
Evidence depth22stories at latest stored reading · +21
Confidence31/100Provisional · +3
20 Jun50 neutral14 Aug 01:16
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
14 Aug 01:1646+031/100 (-6)22 (-1)Provisional
10 Aug 23:5946+037/100 (-1)23 (+1)Measured
09 Aug 23:5946-438/100 (+3)22 (+1)Measured
08 Aug 23:5950+035/100 (-3)21 (+1)Provisional
06 Aug 23:5950+338/100 (+2)20 (+2)Measured
04 Aug 23:5947-436/100 (+2)18 (0)Provisional
02 Aug 23:5951+034/100 (+1)18 (+1)Provisional
01 Aug 23:5951+433/100 (-2)17 (-2)Provisional

Source headlines

The news behind the score

Showing 1-20 of 20

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#221Tone
The National Law ReviewDirect company coverageStored article

RGC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit, filed on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, alleges the company made materially false and misleading statements regarding its business and operations, exposing investors to significant financial risk and regulatory scrutiny due to market manipulation. Investors with substantial losses have until June 23, 2026, to request to be appointed as lead plaintiff.

FinanceFinancial Markets
Published
09 Aug 2026 23:41
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Company discussed · 86%
How it is used
Direct company coverage
Weighted influence
High · 31.9% · 4.1d old
Duplicates
1 consolidated
#373Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Regencell Bioscience Holdings Ltd (RGC), detailing future EPS and revenue growth estimates. It highlights the stock's current performance, market capitalization, and includes a peer comparison in the biotechnology and medical research sector. The forecast data was updated on August 8, 2026.

EarningsFinancial MarketsLife Sciences
Published
06 Aug 2026 19:40
News subject
Earnings
Why this score
Operating growth, Growth forecast
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 16.7% · 7.2d old
Duplicates
1 consolidated
#421Tone
The National Law ReviewDirect company coverageStored article

RGC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regencell Bioscience Holdings Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit alleges that Regencell made materially false and misleading statements regarding its business, operations, and compliance policies between October 28, 2024, and October 31, 2025. Investors who purchased Regencell securities during this period have until June 23, 2026, to request to be appointed lead plaintiff in the case.

FinanceLife Sciences
Published
04 Aug 2026 05:40
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
High · 21.3% · 9.8d old
Duplicates
1 consolidated
#550Tone
TradingViewDirect company coverageScored from headlineSource lookup

Regencell Bioscience Holdings Limited Revenue Breakdown – NASDAQ:RGC

Published
02 Aug 2026 15:27
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.8% · 11.4d old
Duplicates
1 consolidated
#650Tone
TradingKeyDirect company coverageScored from headlineSource lookup

Regencell Bioscience Holdings Ltd (RGC) Cash Flow

Published
02 Aug 2026 11:32
News subject
Balance sheet
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 5.1% · 11.6d old
Duplicates
1 consolidated
#773Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Regencell Bioscience Holdings Ltd (RGC), detailing future EPS and revenue growth estimates. It includes a snapshot of RGC's current stock performance, market capitalization, and various analytical dimensions such as valuation, earnings forecast, and risk assessment. The forecast data was updated on August 2, 2026.

EarningsFinanceLife Sciences
Published
01 Aug 2026 04:40
News subject
Earnings
Why this score
Operating growth, Growth forecast
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Low · 5.9% · 12.9d old
Duplicates
1 consolidated
#850Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd (RGC) Cash Flow

This article provides an overview of Regencell Bioscience Holdings Ltd's (RGC) cash flow, including operating, investing, and financing cash flow, along with free cash flow. It details the company's operating cash flow for fiscal 2025, its year-over-year change, and capital expenditures for the most recent quarter. The content also includes definitions and explanations of these financial metrics for investors.

EarningsFinanceLife Sciences
Published
28 Jul 2026 15:13
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.4% · 16.4d old
Duplicates
1 consolidated
#950Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd

This article provides an overview of Regencell Bioscience Holdings Ltd (RGC), including its current stock price, market cap, and stock performance. It notes that revenue breakdown data by business segment and region have not yet been disclosed by the company. The page serves as a financial data portal, offering analysis tools and company information.

EarningsLife Sciences
Published
28 Jul 2026 06:09
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.6% · 16.8d old
Duplicates
1 consolidated
#1041Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd (RGC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Regencell Bioscience Holdings Ltd (RGC), focusing on its volatility, financial risk, and investment risk. It presents various metrics such as Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, Skewness, and Liquidity. The data indicates significant volatility and downside risk for RGC, with specific figures for different timeframes.

Financial MarketsFinanceLife Sciences
Published
27 Jul 2026 14:05
News subject
Market update
Why this score
Negative valuation view
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 17.5d old
Duplicates
1 consolidated
#1150Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd (RGC) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Regencell Bioscience Holdings Ltd (RGC). It details the institutional shareholding and shareholder activity, listing various firms and their stake changes. The data indicates significant institutional interest and varying portfolio adjustments among these investors.

Financial Markets
Published
27 Jul 2026 10:41
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 17.6d old
Duplicates
1 consolidated
#1250Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd (RGC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Regencell Bioscience Holdings Ltd (RGC), detailing various technical indicators and moving averages to assess its current stock performance. It includes a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and STOCH, as well as moving averages (MA5 to MA200). The analysis also features FAQs about technical ratings and moving averages, and offers a general sentiment of "Neutral" based on the combined technical signals.

Financial MarketsLife Sciences
Published
27 Jul 2026 09:41
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 17.6d old
Duplicates
1 consolidated
#1350Tone
TradingKeyDirect company coverageStored article

RGC|Regencell Bioscience Holdings Ltd|Price:5.770|Chg%:+0.050

This article provides a comprehensive stock analysis of Regencell Bioscience Holdings Ltd (RGC) from TradingKey, noting the lack of a stock score due to insufficient data. It details how TradingKey generates various scores, including financial health, company valuation, earnings forecasts, price momentum, institutional confidence, and risk management, explaining the indicators used for each. The article also provides current stock quotes and market capitalization for RGC.

EarningsFinancial MarketsFinanceLife Sciences
Published
27 Jul 2026 02:05
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.3% · 18.0d old
Duplicates
1 consolidated
#1450Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd (RGC) Income Statement

This article provides the quarterly and annual income statements for Regencell Bioscience Holdings Ltd (RGC), offering insights into the company's financial performance and operational efficiency. It details key metrics such as operating expenses, R&D expenses, operating profit, and net income over several fiscal periods, alongside a FAQ section explaining how to interpret the data.

EarningsFinanceLife Sciences
Published
26 Jul 2026 14:43
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.3% · 18.4d old
Duplicates
1 consolidated
#1550Tone
TradingKeyDirect company coverageStored article

Regencell Bioscience Holdings Ltd RGC Balance Sheet

This article provides a detailed balance sheet for Regencell Bioscience Holdings Ltd (RGC), presenting both quarterly and annual financial data spanning several fiscal years. It includes key financial metrics such as total equity, cash and short-term investments, total assets, liabilities, and shareholders' equity. The data allows for evaluation of the company's financial health, liquidity, leverage, and return on equity trends.

EarningsFinanceFinancial MarketsLife Sciences
Published
25 Jul 2026 10:44
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.1% · 19.6d old
Duplicates
2 consolidated
#1623Tone
MarketBeatDirect company coverageStored article

Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.2% - Time to Sell?

Regencell Bioscience (NASDAQ:RGC) stock fell 7.2% on Wednesday, with trading volume significantly lower than average. Analyst sentiment remains negative, with both Wall Street Zen and Weiss Ratings issuing "sell" recommendations. The stock is trading well below its 50-day and 200-day moving averages, indicating a severe recent decline.

EarningsFinancial MarketsLife Sciences
Published
22 Jul 2026 15:41
News subject
Earnings
Why this score
Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.1% · 22.4d old
Duplicates
1 consolidated
#1750Tone
MarketBeatDirect company coverageStored article

Regencell Bioscience (NASDAQ:RGC) Trading 12% Higher - Should You Buy?

Regencell Bioscience (NASDAQ:RGC) experienced a 12% jump in its share price on Tuesday, trading as high as $5.67 before closing at $5.71, despite a significant drop in trading volume. This surge occurs against a backdrop of negative analyst ratings, with Weiss Ratings reiterating a "sell" and Wall Street Zen downgrading the stock to "sell," resulting in an overall "Sell" rating from MarketBeat data. The company's stock continues to trade well below its longer-term moving averages, and it recently reported flat EPS for the quarter.

Financial MarketsLife SciencesFinanceEarnings
Published
21 Jul 2026 17:11
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.6% · 23.3d old
Duplicates
1 consolidated
#1821Tone
Investing.com CanadaDirect company coverageStored article

Regencell Bioscience stock hits 52-week low at 4.91 USD By Investing.com

Regencell Bioscience Holdings Ltd (RGC) stock fell to a new 52-week low of $4.91, marking a significant decline of 66.02% over the past year and 76% year-to-date. The company, now with a market capitalization of $2.58 million, recently announced a $20 million direct offering of ordinary shares and changed its independent registered public accounting firm from Marcum Asia CPAs LLP to HTL International, LLC. Despite its low price, InvestingPro analysis rates the stock's financial health as "WEAK" and potentially overvalued.

EarningsFinanceFinancial MarketsLife Sciences
Published
16 Jul 2026 14:11
News subject
Earnings
Why this score
Negative market reaction, Negative valuation view
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.4% · 28.5d old
Duplicates
4 consolidated
#1950Tone
ChartMillDirect company coverageScored from headlineSource lookup

RGC News | REGENCELL BIOSCIENCE HOLDING (NASDAQ:RGC)

Published
15 Jul 2026 11:24
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 29.6d old
Duplicates
1 consolidated
#2021Tone
The National Law ReviewDirect company coverageStored article

RGC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Regencell Bioscience Holdings Ltd. to Contact the Firm Today!

Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025. The lawsuit alleges that Regencell made materially false and misleading statements, exposing investors to significant financial risk due to market manipulation and potential regulatory scrutiny. Investors who suffered losses are encouraged to contact the firm by June 23, 2026, to discuss lead plaintiff opportunities.

Life SciencesFinance
Published
15 Jul 2026 05:42
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.9% · 29.8d old
Duplicates
1 consolidated

Earlier company news

RGC news archive

Showing 1-9 of 9 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Provider matches checked

Provider mentions not used in the score

5 not scored

A news provider linked these stories to RGC, but the headline and available text are not mainly about Regencell Bioscience Holdings Ltd. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of RGC sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context